These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 1490801)

  • 1. Pharmacokinetics of trapidil (Rocornal) in patients with chronic liver disease.
    Berndt A; Pönicke K; Weiss M
    Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):492-3. PubMed ID: 1490801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of trapidil in patients with chronic liver disease.
    Berndt A; Looby M; Pönicke K; Zipprich B; Weiss M
    J Clin Pharmacol; 1996 Oct; 36(10):897-902. PubMed ID: 8930776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cimetidine in patients with liver disease.
    González-Martin G; Arancibia A; Fajuri M; Chesta J; Novoa X
    Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):355-8. PubMed ID: 4030163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of trapidil tablets.
    Weiss M; Sziegoleit W; Pönicke K; Schobess M; Fahr A; Mest HJ
    Arzneimittelforschung; 1989 Sep; 39(9):1137-8. PubMed ID: 2590264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Modification of pulmonary hypertension in patients with chronic obstructive lung diseases by trapidil (Rocornal) in an acute trial].
    Schauer J; Orschekowski H; Winkler J; Steiniger L
    Z Erkr Atmungsorgane; 1991; 177(3):204-16. PubMed ID: 1808871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of hepatic disease on the pharmacokinetics of famotidine and effects of famotidine on hepatic hemodynamics and peptic ulcer.
    Ohnishi K
    Hepatogastroenterology; 1990 Jul; 37 Suppl 1():6-10. PubMed ID: 2210613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeine clearance by two point analysis: a measure of liver function in chronic liver disease.
    Wittayalertpanya S; Israsena S; Thamaree S; Tongnopnoua P; Komolmit P
    Tokai J Exp Clin Med; 1996 Dec; 21(4-6):195-201. PubMed ID: 9300980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeine elimination in cirrhotic and non-cirrhotic liver disease of different etiology.
    Joeres R; Brachtel D; Gallenkamp H; Hofstetter G; Klinker H; Zilly W; Richter E
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():56-61. PubMed ID: 7483716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum leptin levels in patients with nonalcoholic chronic liver disease.
    Nakamuta M; Tada S; Uchimura K; Enjoji M; Kinukawa N; Iwamoto H; Sugimoto R; Shimada M; Ohashi M; Sugimachi K; Nawata H
    Hepatogastroenterology; 2001; 48(38):527-32. PubMed ID: 11379347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow].
    Nomura F; Ohnishi K; Ohto M; Takeda Y; Rikihisa T; Kanakubo Y
    Rinsho Byori; 1991 Oct; 39(10):1093-7. PubMed ID: 1762184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced external counterpulsation: a new technique to augment renal function in liver cirrhosis.
    Werner D; Trägner P; Wawer A; Porst H; Daniel WG; Gross P
    Nephrol Dial Transplant; 2005 May; 20(5):920-6. PubMed ID: 15788437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of famotidine after intravenous administration in liver disease.
    Ohnishi K
    Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
    Ohnhaus EE; Münch U; Meier J
    Schweiz Med Wochenschr; 1976 Dec; 106(49):1748-50. PubMed ID: 1013699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of the PDGF-antagonist trapidil in patients with and without renal impairment.
    Thürmann PA; Harder S; Wolter K; Münck AC; Fritschka E
    Clin Nephrol; 1997 Feb; 47(2):99-105. PubMed ID: 9049457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes in plasma vitronectin, fibronectin, and serum laminin P1 levels and immunohistochemical study of vitronectin in the liver of patients with chronic liver diseases].
    Tomihira M
    Fukuoka Igaku Zasshi; 1991 Jan; 82(1):21-30. PubMed ID: 1708742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis.
    Kaser S; Moschen A; Kaser A; Ludwiczek O; Ebenbichler CF; Vogel W; Jaschke W; Patsch JR; Tilg H
    J Intern Med; 2005 Sep; 258(3):274-80. PubMed ID: 16115302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status.
    Zapater P; Lasso de la Vega MC; Horga JF; Such J; Frances R; Esteban A; Palazòn JM; Carnicer F; Pascual S; Pérez-Mateo M
    Aliment Pharmacol Ther; 2004 Jul; 20(1):29-36. PubMed ID: 15225168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biliary excretion of mezlocillin in patients with hepatic disease.
    Hildebrandt R; Gundert-Remy U; Raedsch R; Sieg A; Stiehl A
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):384-7. PubMed ID: 7582392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnostic value of the study of caffeine elimination in chronic liver diseases].
    Darnót G; Nemesánszky E; Bariska J
    Orv Hetil; 1995 Apr; 136(18):927-32. PubMed ID: 7739851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranitidine disposition in severe hepatic cirrhosis.
    Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.